Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 9:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 61 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Breast Q Clear all
Completed Phase 1Phase 2 Interventional

Phase I-II Study of Carboplatin, Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer

NCT00277069
View directory record Official record
Conditions
Breast, Cancer
Interventions
Carboplatin, Capecitabine, Vinorelbine
Drug · Device
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 6, 2010 · Synced Sep 10, 2026, 9:47 AM EDT
Completed No phase listed Observational

Sensory Morbidity Following Breast Surgery

NCT00625924
View directory record Official record
Conditions
Breast Cancer
Interventions
questionnaires
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 15, 2014 · Synced Sep 10, 2026, 9:47 AM EDT
Completed Phase 1 Interventional Results available

Optimizing Decision Making About Breast Reconstruction After Mastectomy: A Patient-Centered Approach

NCT03346161
View directory record Official record
Conditions
Breast Cancer
Interventions
Usual care American Society of Plastic Surgeons booklet "Breast Reconstruction", Decision tool, Usual Care Group - Outcome Measures, Decision Group - Outcome Measures, Demographic and Background Questions
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced Sep 10, 2026, 9:47 AM EDT
Terminated Phase 1 Interventional Results available

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

NCT05035407
View directory record Official record
Conditions
Kita-kyushu Lung Cancer Antigen 1, Human
Interventions
IL-2 (Aldesleukin), Cyclophosphamide, KK-LC-1 TCR, Fludarabine, EKG, CXR, CT, MRI, PET, Biopsy, Acetaminophen, Ondansetron, Meperidine, Indomethacin, Famotidine
Drug · Biological · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Sep 10, 2026, 9:47 AM EDT
Completed Phase 2 Interventional Results available

Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer

NCT00482391
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, cyclophosphamide, doxorubicin hydrochloride, lapatinib ditosylate, paclitaxel, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Sep 10, 2026, 9:47 AM EDT
Terminated No phase listed Observational

Long Term Function Outcomes and Pain in Implant-based Post-mastectomy Breast Reconstruction

NCT04477538
View directory record Official record
Conditions
Post-mastectomy Breast Reconstruction
Interventions
Post-mastectomy breast reconstruction physical well-being survey
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Sep 10, 2026, 9:47 AM EDT
Completed No phase listed Observational

Autologous Fat Grafting of the Breast in Women With Post Lumpectomy Contour Defects

NCT02302196
View directory record Official record
Conditions
Cancer of the Breast, Anomaly of Breast
Interventions
Autologous Fat Grafting of the Breast, Control Arm
Procedure · Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Clackamas, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Sep 10, 2026, 9:47 AM EDT
Completed Phase 4 Interventional

MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I

NCT01501487
View directory record Official record
Conditions
Breast Cancer
Interventions
TAC chemotherapy, TC chemotherapy, Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy, TCH chemotherapy, T + trastuzumab followed by CEF + trastuzumab, Dose dense AC followed by T + trastuzumab, Dose dense AC followed by T + trastuzumab + pertuzumab, PTH followed by dose dense AC of FEC
Drug
Lead sponsor
Agendia
Industry
Eligibility
18 Years and older · Female only
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
9
States / cities
Mobile, Alabama • Clearwater, Florida • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Sep 10, 2026, 9:47 AM EDT
Withdrawn Not applicable Interventional

Breast Reconstruction Following Breast Cancer in Very High Risk Patients

NCT03261323
View directory record Official record
Conditions
Breast Cancer, Malignant Neoplasm of Breast
Interventions
Immediate Breast Reconstruction, Delayed Breast Reconstruction, Breast-Q questionnaire
Procedure · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
19 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 19, 2022 · Synced Sep 10, 2026, 9:47 AM EDT
Completed Not applicable Interventional Results available

Blossom Smart Expander Technology in Breast Reconstruction in Participants With Breast Cancer Undergoing Mastectomy

NCT03657069
View directory record Official record
Conditions
Breast Carcinoma, Breast Disorder
Interventions
Blossom, Breast-Q -Reconstruction module (preoperative) version 2.0 satisfaction with breasts questionnaire
Device · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2024 · Synced Sep 10, 2026, 9:47 AM EDT
Completed Not applicable Interventional

Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility

NCT00617370
View directory record Official record
Conditions
Breast Cancer, Adenocarcinoma of the Breast
Interventions
epirubicin, cyclophosphamide, Paclitaxel,
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Sep 10, 2026, 9:47 AM EDT
Active, not recruiting Not applicable Interventional

Use of an Interactive 3D Tool During Consultation for Breast Reconstruction Surgery

NCT05025020
View directory record Official record
Conditions
Breast Cancer
Interventions
interactive 3D tool, BREAST-Q Reconstruction Module, DQI, Ottawa Decision Regret Scale
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 10, 2026, 9:47 AM EDT
Terminated Phase 2 Interventional Results available

Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Breast Cancer

NCT01010854
View directory record Official record
Conditions
Breast Cancer
Interventions
VPA FEC100
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Sep 10, 2026, 9:47 AM EDT
Active, not recruiting Phase 2 Interventional

Olaparib In Metastatic Breast Cancer

NCT03344965
View directory record Official record
Conditions
Metastatic Breast Cancer, Invasive Breast Cancer, Somatic Mutation Breast Cancer (BRCA1), Somatic Mutation Breast Cancer (BRCA2), CHEK2 Gene Mutation, ATM Gene Mutation, PALB2 Gene Mutation, RAD51 Gene Mutation, BRIP1 Gene Mutation, NBN Gene Mutation
Interventions
Olaparib
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
20
States / cities
Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced Sep 10, 2026, 9:47 AM EDT
Completed Not applicable Interventional

Development of a Questionnaire to Evaluate Patient Expectations for Breast Reconstruction in Women With Breast Cancer or Other Conditions

NCT00471601
View directory record Official record
Conditions
Breast Cancer
Interventions
counseling intervention, questionnaire administration, psychosocial assessment and care, quality-of-life assessment
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2023
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Sep 10, 2026, 9:47 AM EDT
Completed No phase listed Observational

Sexual Health in Breast Cancer Patients

NCT05138510
View directory record Official record
Conditions
Breast Cancer
Interventions
Focus Group
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older · Female only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 10, 2026, 9:47 AM EDT
Terminated Phase 2 Interventional

Shave Margins in Breast Conservation Therapy

NCT02462200
View directory record Official record
Conditions
Breast Cancer, Cancer of Breast, Cancer of the Breast
Interventions
Breast-conserving surgery (BCS), Cavity shave margins (CSM), BREAST-Q Questionnaire, 3-D breast imaging, Indocyanine green, Intraoperative imaging device, Peripheral blood draw
Procedure · Behavioral · Device + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 24, 2020 · Synced Sep 10, 2026, 9:47 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer

NCT02139358
View directory record Official record
Conditions
Breast Cancer
Interventions
Gemcitabine, Trastuzumab, Pertuzumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Sep 10, 2026, 9:47 AM EDT
Completed No phase listed Observational

QOL Assessment in Breast Cancer Patients With Radiation-Induced Telangiectasias Treated With the Pulsed Dye Laser

NCT01803516
View directory record Official record
Conditions
Breast Cancer, Radiation-Induced Telangiectasias
Interventions
questionnaires
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Sep 10, 2026, 9:47 AM EDT
Terminated Phase 2 Interventional Results available

Glutamine for the Prevention of Radiation Toxicity in Subjects Conserving Therapy

NCT02012608
View directory record Official record
Conditions
Breast Cancer
Interventions
Glutamine, Placebo
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Sep 10, 2026, 9:47 AM EDT
Recruiting Not applicable Interventional

Effect of Prenatal and Postnatal Intervention Strategies on Breastfeeding Outcomes in Women With Excessive Weight (Ready, Set, Nourish Study)

NCT06929091
View directory record Official record
Conditions
Breastfeeding, Dietary Intervention, Milk Expression, Breast
Interventions
Lactation Support and ABME, Lactation Support and meal plan, Lactation Support
Other
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Sep 10, 2026, 9:47 AM EDT
Completed Phase 1 Interventional

Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year

NCT00424983
View directory record Official record
Conditions
Multiple Myeloma, Breast Cancer
Interventions
Zoledronic acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
7
States / cities
West Hollywood, California • Greenwood Village, Colorado • Norwalk, Connecticut + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Sep 10, 2026, 9:47 AM EDT
Completed Phase 2 Interventional Results available

Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa

NCT01670500
View directory record Official record
Conditions
Breast Cancer
Interventions
Cisplatin, Cyclophosphamide, Doxorubicin
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
15
States / cities
Aurora, Colorado • Derby, Connecticut • Guilford, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 10, 2026, 9:47 AM EDT
Terminated Phase 2 Interventional

Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer

NCT05163223
View directory record Official record
Conditions
Breast Cancer
Interventions
AST-301(pNGVL3-hICD), rhuGM-CSF, Placebo, Pembrolizumab, Capecitabine
Biological · Drug
Lead sponsor
Aston Sci. Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Chandler, Arizona • La Jolla, California • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2024 · Synced Sep 10, 2026, 9:47 AM EDT